Onyewuchi Onyinyechukwu Joy
Research Subjects
Research Interests
Onyewuchi Onyinyechukwu Joy has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Chinyere Elohor Egbordi1 shared publication
- Hussaini Abba Disa1 shared publication
- Kehinde Jonathan Irhodia
Department of Biotechnology, School of Life Science, Federal University of Technology, Akure, Ondo, Nigeria
1 shared publication - Obiageri Ihuarulam Okeoma
Department of Medical Laboratory Science, Faculty of Basic Medical And Applied Sciences, Trinity University, Yaba, Lagos, Nigeria
1 shared publication - Osefanmen Matthew Enosolease1 shared publication
- Uchechukwu Bethel Abioke
Department of Physiotherapy, Faculty of Basic Medical Sciences, University of Benin, Benin, Nigeria
1 shared publication
Latest Publications
- 23 May 2026
- Published by IK Press in Journal of International Research in Medical and Pharmaceutical Sciences
- Vol. 21 (3) , 35-47
From Gut to Brain: The Neurohormonal Basis of Appetite Suppression and Gastric Emptying Delay by Semaglutide in Non-Diabetic Obesity
Background: Obesity is a chronic disease that is caused by dysregulation of the neurohormonal systems that regulate energy balance. With a weight loss of around 15% in randomized phase 3 trials, Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) with greater weight-loss results than any other approved pharmacotherapy. The efficacy is due to the concurrent activation of hypothalamic appetite pathways, peripheral satiety hormones and enteric motility pathways. Methods: A narrative review of peer-reviewed literature was performed from 2015 to 2026. The following databases were searched: PubMed (MEDLINE), Scopus, and Google Scholar. The evidence was categorized in five mechanistic areas: the pharmacology of GLP-1 receptor, hypothalamic control of appetite and energy expenditure, peripheral satiety hormones, gut-brain axis signaling, and gastric motility. The strength of the evidence is indicated throughout, based on randomized trials, preclinical models, or observational studies. Results: Semaglutide acts directly in the arcuate nucleus on GLP-1 receptor (GLP-1R) to inhibit orexigenic (for eating) NPY/AgRP neurons and enhance anorexigenic (appetite suppressant) POMC/CART signaling. This central effect is further enhanced by peripheral ghrelin suppression, increased postprandial insulin secretion, and increased vagal afferent satiety signals. Gastric emptying delay (via enteric GLP-1 receptor activation, vagal efferent cholinergic drive, and suppression of motilin) extends postprandial gastric distention, which strengthens the central satiety signal. This gastric effect is most significant when dosed initially for dose titration and then may decrease following chronic dosing. Conclusion: Semaglutide acts directly in the arcuate nucleus on GLP-1 receptor (GLP-1R) to inhibit orexigenic (for eating) NPY/AgRP neurons and enhance anorexigenic (appetite suppressant) POMC/CART signaling. This central effect is further enhanced by peripheral ghrelin suppression, increased postprandial insulin secretion, and increased vagal afferent satiety signals. Gastric emptying delay (via enteric GLP-1 receptor activation, vagal efferent cholinergic drive, and suppression of motilin) extends postprandial gastric distention, which strengthens the central satiety signal. This gastric effect is most significant when dosed initially for dose titration and then may decrease following chronic dosing.
- 23 May 2026
- Published by IK Press in Journal of International Research in Medical and Pharmaceutical Sciences
- Vol. 21 (3) , 35-47
From Gut to Brain: The Neurohormonal Basis of Appetite Suppression and Gastric Emptying Delay by Semaglutide in Non-Diabetic Obesity
Background: Obesity is a chronic disease that is caused by dysregulation of the neurohormonal systems that regulate energy balance. With a weight loss of around 15% in randomized phase 3 trials, Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) with greater weight-loss results than any other approved pharmacotherapy. The efficacy is due to the concurrent activation of hypothalamic appetite pathways, peripheral satiety hormones and enteric motility pathways. Methods: A narrative review of peer-reviewed literature was performed from 2015 to 2026. The following databases were searched: PubMed (MEDLINE), Scopus, and Google Scholar. The evidence was categorized in five mechanistic areas: the pharmacology of GLP-1 receptor, hypothalamic control of appetite and energy expenditure, peripheral satiety hormones, gut-brain axis signaling, and gastric motility. The strength of the evidence is indicated throughout, based on randomized trials, preclinical models, or observational studies. Results: Semaglutide acts directly in the arcuate nucleus on GLP-1 receptor (GLP-1R) to inhibit orexigenic (for eating) NPY/AgRP neurons and enhance anorexigenic (appetite suppressant) POMC/CART signaling. This central effect is further enhanced by peripheral ghrelin suppression, increased postprandial insulin secretion, and increased vagal afferent satiety signals. Gastric emptying delay (via enteric GLP-1 receptor activation, vagal efferent cholinergic drive, and suppression of motilin) extends postprandial gastric distention, which strengthens the central satiety signal. This gastric effect is most significant when dosed initially for dose titration and then may decrease following chronic dosing. Conclusion: Semaglutide acts directly in the arcuate nucleus on GLP-1 receptor (GLP-1R) to inhibit orexigenic (for eating) NPY/AgRP neurons and enhance anorexigenic (appetite suppressant) POMC/CART signaling. This central effect is further enhanced by peripheral ghrelin suppression, increased postprandial insulin secretion, and increased vagal afferent satiety signals. Gastric emptying delay (via enteric GLP-1 receptor activation, vagal efferent cholinergic drive, and suppression of motilin) extends postprandial gastric distention, which strengthens the central satiety signal. This gastric effect is most significant when dosed initially for dose titration and then may decrease following chronic dosing.
- 23 May 2026
- Published by IK Press in Journal of International Research in Medical and Pharmaceutical Sciences
- Vol. 21 (3) , 1-19
Optimising Insulin Therapy in Modern Type 2 Diabetes Care: A Narrative Review
Background: Type 2 diabetes mellitus is a chronic metabolic condition affecting millions of adults worldwide. Despite newer treatment modalities such as GLP-1 receptor agonists, SGLT2 inhibitors, and tirzepatide, insulin remains vital for many patients. This is particularly the case for those with advanced beta-cell dysfunction, severe hyperglycaemia, or inadequate glycaemic control despite non-insulin therapies. Objective: This narrative review outlines the changing landscape of insulin therapy for type 2 diabetes, and focuses on personalisation of treatment, combination therapy, minimising adverse events, digital technologies and safe de-intensification. Methods: Literature was reviewed from PubMed, Scopus, and Google Scholar, focusing mainly on clinical trials, systematic reviews, meta-analyses, major guidelines, and relevant expert reviews published between 2016 and 2026. Landmark older studies were included where clinically relevant. Key Findings: The use of insulin is still strongly influencing glycaemic control but is now more guided by new therapies and technologies. GLP-1 receptor agonists, SGLT2 inhibitors, and tirzepatide can be combined to lower the amount of insulin needed for treatment, help prevent weight gain, improve cardiometabolic outcomes, and decrease treatment burden in certain patients. New technologies such as smart insulin pens and digital titration devices facilitate more accurate insulin dosing and decrease the risk of hypoglycaemia. Patient-led titration and safe de-intensification are also important particularly for high-risk individuals for hypoglycaemia. Conclusion: Insulin therapy remains indispensable in type 2 diabetes care, but its optimal use now requires a more digitally supported, and patient-centred approach. The key concern is no longer whether insulin remains necessary, but how its use can be optimised to improve effectiveness and fit safely within modern type 2 diabetes care.
- 23 May 2026
- Published by IK Press in Journal of International Research in Medical and Pharmaceutical Sciences
- Vol. 21 (3) , 1-19
Optimising Insulin Therapy in Modern Type 2 Diabetes Care: A Narrative Review
Background: Type 2 diabetes mellitus is a chronic metabolic condition affecting millions of adults worldwide. Despite newer treatment modalities such as GLP-1 receptor agonists, SGLT2 inhibitors, and tirzepatide, insulin remains vital for many patients. This is particularly the case for those with advanced beta-cell dysfunction, severe hyperglycaemia, or inadequate glycaemic control despite non-insulin therapies. Objective: This narrative review outlines the changing landscape of insulin therapy for type 2 diabetes, and focuses on personalisation of treatment, combination therapy, minimising adverse events, digital technologies and safe de-intensification. Methods: Literature was reviewed from PubMed, Scopus, and Google Scholar, focusing mainly on clinical trials, systematic reviews, meta-analyses, major guidelines, and relevant expert reviews published between 2016 and 2026. Landmark older studies were included where clinically relevant. Key Findings: The use of insulin is still strongly influencing glycaemic control but is now more guided by new therapies and technologies. GLP-1 receptor agonists, SGLT2 inhibitors, and tirzepatide can be combined to lower the amount of insulin needed for treatment, help prevent weight gain, improve cardiometabolic outcomes, and decrease treatment burden in certain patients. New technologies such as smart insulin pens and digital titration devices facilitate more accurate insulin dosing and decrease the risk of hypoglycaemia. Patient-led titration and safe de-intensification are also important particularly for high-risk individuals for hypoglycaemia. Conclusion: Insulin therapy remains indispensable in type 2 diabetes care, but its optimal use now requires a more digitally supported, and patient-centred approach. The key concern is no longer whether insulin remains necessary, but how its use can be optimised to improve effectiveness and fit safely within modern type 2 diabetes care.